Date: 2015-07-21
Type of information: Nomination
Compound:
Company: Ares Allergy (UK)
Therapeutic area: Allergic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 21, 2015, following the approval by the shareholders’ meeting of Stallergenes of 26 June 2015 of the pending merger with Ares Allergy, the newly formed board of directors appointed Fereydoun Firouz its Chairman and Chief Executive Officer at its meeting today. Fereydoun brings extensive experience in global commercial markets, and a strong record of accomplishment in identifying growth opportunities and building value in businesses around the world. Fereydoun Firouz joins Ares Allergy from Gurnet Point Capital LLC, the US healthcare and life science investment fund, where he was a Managing Partner. Prior to this, he was President and CEO of Merck Serono US and a member of the Executive Management Board of Merck Serono. The merger is expected to close in September 2015 at a date to be set by the English Court after the shareholders\' meeting of Ares Allergy approves the merger on 4 August 2015. Upon completion of the merger, the shares of Stallergenes will be delisted from Euronext Paris and the shares of Ares Allergy listed on Euronext Paris.
Financial terms:
Latest news:
